Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial
- Resource Type
- Article
- Source
- In
Clinical Breast Cancer June 2016 16(3):180-187 - Subject
- Language
- ISSN
- 1526-8209